Основные положения нового варианта рекомендаций по профилактике, выявлению, оценке и лечению повышенного уровня артериального давления Американской коллегии кардиологов/Американской ассоциации кардиологов и ряда других профессиональных медицинских обществ США (Часть 3)

  • Редакция
Журнал: Доказательная кардиология (электронная версия, архив до 2019). 2018;11(3): 25-44
Просмотрено: 1407 Скачано: 371
Источник: Whelton P.K., Carey R.M., Aronow W.S., et al. 2017. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension 2018;71:e13—e115. https://doi.org/10.1161/HYP.0000000000000065. 2017


Редакция Основные положения нового варианта рекомендаций по профилактике, выявлению, оценке и лечению повышенного уровня артериального давления Американской коллегии кардиологов/Американской ассоциации кардиологов и ряда других профессиональных медицинских обществ США (Часть 3). Доказательная кардиология (электронная версия, архив до 2019). 2018;11(3):25-44.

Список литературы:

  1. Lloyd-Jones D.M., Evans J.C., Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005;294:466—472.
  2. Ozyilmaz A., Bakker S.J.L., de Zeeuw D., et al. Screening for albuminuria with subsequent screening for hypertension and hypercholesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events. Nephrol Dial Transplant 2013;28:2805—2815.
  3. Peters S.A.E., Huxley R.R., Woodward M. Comparison of the sex-specific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals. Stroke 2013;44:2394—2401.
  4. Schoenfeld S.R., Kasturi S., Costenbader K.H. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 2013;43:77—95.
  5. Lawes C.M.M., Bennett D.A., Lewington S., et al. Blood pressure and coronary heart disease: a review of the evidence. Semin Vasc Med 2002;2:355—368.
  6. Lewington S., Clarke R., Qizilbash N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903—1913.
  7. Takashima N., Ohkubo T., Miura K., et al. Long-term risk of BP values above normal for cardiovascular mortality: a 24-year observation of Japanese aged 30 to 92 years. J Hypertens 2012;30:2299—2306.
  8. Murakami Y. Meta-analyses using individual participant data from cardiovascular cohort studies in Japan: current status and future directions. J Epidemiol 2014;24:96—101.
  9. van Dieren S., Kengne A.P., Chalmers J., et al. Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. Diabetes Res Clin Pract 2012;98:83—90.
  10. Sundstrom J., Arima H., Woodward M., et al. Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 2014;384:591—598.
  11. Turnbull F., Neal B., Algert C., et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410—1419.
  12. Wang J.-G., Staessen J.A., Franklin S.S., et al. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005;45:907—913.
  13. Turnbull F., Woodward M., Neal B., et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 2008;29:2669—2680.
  14. Turnbull F., Neal B., Ninomiya T., et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121—1123.
  15. Du X., Ninomiya T., de Galan B., et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009;30:1128—1135.
  16. Czernichow S., Ninomiya T., Huxley R., et al. Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial. Hypertension 2010;55:1193—1198.
  17. Heerspink H.J.L., Ninomiya T., Perkovic V., et al. Effects of a fixed combination of perindopril and indapamidein patients with type 2 diabetes and chronic kidney disease. Eur Heart J 2010;31:2888—2896.
  18. Ninomiya T., Zoungas S., Neal B., et al. Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. J Hypertens 2010;28:1141—1149.
  19. Collier D.J., Poulter N.R., Dahlof B., et al. Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). J Hypertens 2011;29:583—591.
  20. Ninomiya T., Perkovic V., Turnbull F., et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. BMJ 2013;347:f5680.
  21. Redon J., Mancia G., Sleight P., et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol 2012;59:74—83.
  22. Ogden L.G., He J., Lydick E., et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000;35:539—543.
  23. van der Leeuw J., Visseren F.L.J., Woodward M., et al. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation. Hypertension 2015;65:115—121.
  24. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
  25. Ettehad D., Emdin C.A., Kiran A., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957—967.
  26. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels — overview and meta-analyses of randomized trials. J Hypertens 2014;32:2296—2304.
  27. Sundstrom J., Arima H., Jackson R., et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 2015;162:184—191.
  28. Thompson A.M., Hu T., Eshelbrenner C.L., et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 2011;305:913—922.
  29. Xie X., Atkins E., Lv J., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435—443.
  30. Wright J.T. Jr, Williamson J.D., Whelton P.K., et al. A randomized trial of intensive versus standard blood-pressure control. SPRINT Research Group. N Engl J Med 2015;373:2103—2116.
  31. Czernichow S., Zanchetti A., Turnbull F., et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 2011;29:4—16.
  32. Montgomery A.A., Fahey T., Ben-Shlomo Y., et al. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis. J Hypertens 2003;21:1753—1759.
  33. Kassai B., Boissel J.-P., Cucherat M., et al. Treatment of high blood pressure and gain in event-free life expectancy. Vasc Health Risk Manag 2005;1:163—169.
  34. Rubinstein A., Colantonio L., Bardach A., et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health 2010;10:627.
  35. Baker S., Priest P., Jackson R. Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. BMJ 2000;320:680—685.
  36. Gaziano T.A., Steyn K., Cohen D.J., et al. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation 2005;112:3569—3576.
  37. Eddy D.M., Adler J., Patterson B., et al. Individualized guidelines: the potential for increasing quality and reducing costs. Ann Intern Med 2011;154:627—634.
  38. Marchant I., Nony P., Cucherat M., et al. The global risk approach should be better applied in French hypertensive patients: a comparison between simulation and observation studies. PLoS ONE 2011;6:e17508.
  39. Cadilhac D.A., Carter R., Thrift A.G., et al. Organized blood pressure control programs to prevent stroke in Australia: would they be cost-effective? Stroke 2012;43:1370—1375.
  40. Cobiac L.J., Magnus A., Barendregt J.J., et al. Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study. BMC Public Health 2012;12:398.
  41. Cobiac L.J., Magnus A., Lim S., et al. Which interventions offer best value for money in primary prevention of cardiovascular disease? PLoS ONE 2012;7:e41842.
  42. Karmali K.N., Lloyd-Jones D.M. Global risk assessment to guide blood pressure management in cardiovascular disease prevention. Hypertension 2017;69:e2—9.
  43. Muntner P., Whelton P.K. Using predicted cardiovascular disease risk in conjunction with blood pressure to guide antihypertensive medication treatment. J Am Coll Cardiol 2017;69:2446—2456.
  44. Sussman J., Vijan S., Hayward R. Using benefit-based tailored treatment to improve the use of antihypertensive medications. Circulation 2013;128:2309—2317.
  45. van der Leeuw J., Ridker P.M., van der Graaf Y., et al. Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects. Eur Heart J 2014;35:837—843.
  46. Mendis S., Lindholm L.H., Mancia G., et al. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens 2007;25:1578—1582.
  47. van Dis I., Geleijnse J.M., Verschuren W.M.M., et al. Cardiovascular risk management of hypertension and hypercholesterolaemia in the Netherlands: from unifactorial to multifactorial approach. Neth Heart J 2012;20:320—325.
  48. Nelson M.R., Doust J.A. Primary prevention of cardiovascular disease: new guidelines, technologies and therapies. Med J Aust 2013;198:606—610.
  49. JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014;100(suppl 2):ii1—67.
  50. World Health Organization. Prevention of Cardiovascular Disease. Guidelines for Assessment and Management of Cardiovascular Risk. Geneva, Switzerland: World Health Organization; 2007.
  51. Anderson J.L., Heidenreich P.A., Barnett P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2304—2322.
  52. Sheridan S.L., Crespo E. Does the routine use of global coronary heart disease risks cores translate into clinical benefits or harms? A systematic review of the literature. BMC Health Serv Res 2008;8:60.
  53. Sheridan S.L., Viera A.J., Krantz M.J., et al. The effect of giving global coronary risk in formation to adults: a systematic review. Arch Intern Med 2010;170:230—239.
  54. Viera A.J., Sheridan S.L. Global risk of coronary heart disease: assessment and application. Am Fam Physician 2010;82:265—274.
  55. Sheridan S.L., Draeger L.B., Pignone M.P., et al. A randomized trial of an intervention to improve use and adherence to effective coronary heart disease prevention strategies. BMC Health Serv Res 2011;11:331.
  56. Brett T., Arnold-Reed D., Phan C., et al. The Fremantle Primary Prevention Study: a multicenter randomized trial of absolute cardiovascular risk reduction. Br J Gen Pract 2012;62:e22—28.
  57. Sekaran N.K., Sussman J.B., Xu A., et al. Providing clinicians with a patient’s 10-year cardiovascular risk improves their statin prescribing: a true experiment using clinical vignettes. BMC Cardiovasc Disord 2013;13:90.
  58. Sheridan S.L., Draeger L.B., Pignone M.P., et al. The effect of a decision aid intervention on decision making about coronary heart disease risk reduction: secondary analyses of a randomized trial. BMC Med Inform Decis Mak 2014;14:14.
  59. Jansen J., Bonner C., McKinn S., et al. General practitioners’ use of absolute risk versus individual risk factors in cardiovascular disease prevention: an experimental study. BMJ Open 2014;4:e004812.
  60. Vagholkar S., Zwar N., Jayasinghe U.W., et al. Influence of cardiovascular absolute risk assessment on prescribing of antihypertensive and lipid-lowering medications: a cluster randomized controlled trial. Am Heart J 2014;167:28—35.
  61. Webster R.J., Heeley E.L., Peiris D.P., et al. Gaps in cardiovascular disease risk management in Australian general practice. Med J Aust 2009;191:324—329.
  62. Rafter N., Connor J., Hall J., et al. Cardiovascular medications in primary care: treatment gaps and targeting by absolute risk. N Z Med J 2005;118:U1676.
  63. Yong T.Y., Phillipov G., Phillips P.J. Management outcomes of patients with type 2 diabetes: targeting the10-year absolute risk of coronary heart disease. Med J Aust 2007;186:622—624.
  64. Frikke-Schmidt R., Tybjærg-Hansen A., Schnohr P., et al. Common clinical practice versus new PRIM score in predicting coronary heart disease risk. Atherosclerosis 2010;213:532—538.
  65. Heeley E.L., Peiris D.P., Patel A.A., et al. Cardiovascular risk perception and evidence—practice gaps in Australian general practice (the AusHEART study). Med J Aust 2010;192:254—259.
  66. Shillinglaw B., Viera A.J., Edwards T., et al. Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of U.S. physicians. BMC Health Serv Res 2012;12:20.
  67. Game F.L., Bartlett W.A., Bayly G.R., et al. Comparative accuracy of cardiovascular risk prediction methods in patients with diabetes mellitus. Diabetes Obes Metab 2001;3:279—286.
  68. Bastuji-Garin S., Deverly A., Moyse D., et al. The Framingham prediction rule is not validin a European population of treated hypertensive patients. J Hypertens 2002;20:1973—1980.
  69. Menotti A., Puddu P.E., Lanti M. The estimate of cardiovascular risk. Theory, tools and problems. Ann Ital Med Int 2002;17:81—94.
  70. de Visser C.L., Bilo H.J.G., Thomsen T.F., et al. Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population. J Intern Med 2003;253:553—562.
  71. Persson M., Carlberg B., Weinehall L., et al. Risk stratification by guidelines compared with risk assessment by risk equations applied to a MONICA sample. J Hypertens 2003;21:1089—1095.
  72. Doust J., Sanders S., Shaw J, et al. Prioritising CVD prevention therapy—absolute risk versus individual riskfactors. Aust Fam Physician 2012;41:805—809.
  73. Allan G.M., Nouri F., Korownyk C., et al. Agreement among cardiovascular disease risk calculators. Circulation. 2013;127:1948—1956.
  74. Diverse Populations Collaborative Group. Prediction of mortality from coronary heart disease among diverse populations: is there a common predictive function? Heart 2002;88:222—228.
  75. van den Hoogen P.C., Feskens E.J., Nagelkerke N.J., et al. The relation between blood pressure and mortalitydueto coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000;342:1—8.
  76. Goff D.C. Jr, Lloyd-Jones D.M., Bennett G., et al. 2013ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2935—2959.
  77. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889—2934.
  78. Ambrosius W.T., Sink K.M., Foy C.G., et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 2014;11:532—546.
  79. Cushman W.C., Grimm R.H. Jr, Cutler J.A., et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007;99:44i—55i.
  80. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators. N Engl J Med 2008;358:1547—1559.
  81. Parving H.-H., Brenner B.M., McMurray J.J.V., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204—2213.
  82. Fried L.F., Emanuele N., Zhang J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892—1903.
  83. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967;202:1028—1034.
  84. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 1979;242:2562—2571.
  85. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265:3255—3264.
  86. Kostis J.B., Cabrera J., Cheng J.Q., et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA 2011;306:2588—2593.
  87. Fretheim A., Odgaard-Jensen J., Brors O., et al. Comparativ effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Med 2012;10:33.
  88. Cushman W.C., Ford C.E., Cutler J.A., et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393—404.
  89. Gradman A.H., Basile J.N., Carter B.L., et al. Combination therapy in hypertension. J Clin Hypertens (Greenwich) 2011;13:146—154.
  90. Cushman W.C., Evans G.W., Byington R.P., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. ACCORD Study Group. N Engl J Med 2010;362:1575—1585.
  91. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels— updated overview and meta-analyses of randomized trials. J Hypertens 2016;34:613—622.
  92. Verdecchia P., Angeli F., Gentile G., et al. More versus less intensive blood pressure-lowering strategy: cumulative evidence and trial sequential analysis. Hypertension 2016;68:642—653.
  93. Bangalore S., Toklu B., Gianos E., et al. Optimal systolic blood pressure target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med 2017;30:707—719.e8.
  94. Bundy J.D., Li C., Stuchlik P., et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol 2017;2:775—781.
  95. Julius S., Nesbitt S.D., Egan B.M., et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006;354:1685—1697.
  96. Lonn E.M., Bosch J., Lopez-Jaramillo P., et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016;374:2009—2020.
  97. Neaton J.D., Grimm R.H. Jr, Prineas R.J., et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993;270:713—724.
  98. Brunstrom M., Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 2016;352:i717.
  99. Lv J., Ehteshami P., Sarnak M.J., et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 2013;185:949—957.
  100. Benavente O.R., Coffey C.S., Conwit R., et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. SPS3 Study Group. Lancet 2013;382:507—515.
  101. Perkovic V., Rodgers A. Redefining blood-pressure targets — SPRINT starts the marathon. N Engl J Med 2015;373:2175—2178.
  102. Reboussin D.M., Allen N.B., Griswold M.E., et al. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018;71:2176—2198. https://doi.org/10.1016/j.jacc.2017.11.004. Epub 2017 Nov 13.
  103. Psaty B.M., Lumley T., Furberg C.D., et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534—2544.
  104. Peart S. Results of MRC (UK) trial of drug therapy for mild hypertension. Clin Invest Med 1987;10:616—620.
  105. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981—2997.
  106. Julius S., Weber M.A., Kjeldsen S.E., et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006;48:385—391.
  107. Ferrucci L., Guralnik J.M., Pahor M., et al. Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older persons become severely disabled. JAMA 1997;277:728—734.
  108. Curtis L.H., Whellan D.J., Hammill B.G., et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med 2008;168:418—424.
  109. Bleumink G.S., Knetsch A.M., Sturkenboom M.C.J.M., et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004;25:1614—1619.
  110. Bertoni A.G., Hundley W.G., Massing M.W., et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004;27:699—703.
  111. Ogedegbe G., Shah N.R., Phillips C., et al. Comparative effectiveness of angiotensin-converting enzyme inhibitor-based treatment on cardiovascular outcomes in hypertensive blacks versus whites. J Am Coll Cardiol 2015;66:1224—1233.
  112. Leenen F.H.H., Nwachuku C.E., Black H.R., et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension 2006;48:374—384.
  113. Zanchetti A., Julius S., Kjeldsen S., et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006;24:2163—2168.
  114. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2003;42:239—246.
  115. Senn S. Individual response to treatment: is it a valid assumption? BMJ 2004;329:966—968.
  116. Xu W., Goldberg S.I., Shubina M., et al. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ 2015;350:h158.
  117. Brennan T., Spettell C., Villagra V., et al. Disease management to promote blood pressure control among African Americans. Popul Health Manag 2010;13:65—72.
  118. Bosworth H.B.., Olsen M.K., Grubber J.M., et al. Two self-management interventions to improve hypertension control: a randomized trial. Ann Intern Med 2009;151:687—695.
  119. Bosworth H.B., Powers B.J., Olsen M.K., et al. Home blood pressure management and improved blood pressure control: results from a randomized controlled trial. Arch Intern Med 2011;171:1173—1180.
  120. Green B.B., Cook A.J., Ralston J.D., et al. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA 2008;299:2857—2867.
  121. Heisler M., Hofer T.P., Schmittdiel J.A., et al. Improving blood pressure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems: the adherence and intensification of medications cluster randomized, controlled pragmatic trial. Circulation 2012;125:2863—2872.
  122. Margolis K.L., Asche S.E., Bergdall A.R., et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA 2013;310:46—56.
  123. Aronow W.S., Fleg J.L., Pepine C.J., et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol 2011;57:2037—2114.
  124. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147—239.
  125. Fihn S.D., Blankenship J.C., Alexander K.P., et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2014;64:1929—1949.
  126. Gerhard-Herman M.D., Gornik H.L., Barrett C., et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017;69:e71—126.
  127. Fox K.M. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782—788.
  128. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669—677.
  129. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145—153.
  130. Leon M.B., Rosing D.R., Bonow R.O., et al. Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris. Am J Cardiol 1981;48:131—139.
  131. Staessen J.A., Fagard R., Thijs L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757—764.
  132. Freemantle N., Cleland J., Young P., et al. Beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730—1737.
  133. de Peuter O.R., Lussana F., Peters R.J.G., et al. A systematic review of selective and non-selective betablockers for prevention of vascular events in patients with acute coronary syndrome or heart failure. Neth J Med 2009;67:284—294.
  134. Yancy C.W., Jessup M., Bozkurt B., et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2016;68:1476—1488.
  135. Visser M., Langlois J., Guralnik J.M., et al. High body fatness, but not low fat-free mass, predicts disability in older men and women: the Cardiovascular Health Study. Am J Clin Nutr 1998;68:584—590.
  136. Goodpaster B.H., Park S.W., Harris T.B., et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci 2006;61:1059—1064.
  137. Butler J., Kalogeropoulos A.P., Georgiopoulou V., et al. Systolic blood pressure and incident heart failure in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study. Heart 2011;97:1304—1311.
  138. Aronow W.S., Ahn C., Kronzon I. Normal left ventricular ejection fraction in older persons with congestive heart failure. Chest 1998;113:867—869.
  139. Goldstein R.E., Boccuzzi S.J., Cruess D., et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991;83:52—60.
  140. Aronow W.S., Ahn C., Kronzon I. Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites. Am J Cardiol 1999;84:611—612, A9.
  141. Gottdiener J.S., McClelland R.L., Marshall R., et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002;137:631—639.
  142. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251—259.
  143. Vasan R.S., Larson M.G., Benjamin E.J., et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999;33:1948—1955.
  144. Amery A., Birkenhager W., Brixko P., et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;1:1349—1354.
  145. Kostis J.B., Davis B.R., Cutler J., et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997;278:212—216.
  146. Beckett N.S., Peters R., Fletcher A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887—1898.
  147. Davis B.R., Kostis J.B., Simpson L.M., et al. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 2008;118:2259—2267.
  148. Piller L.B., Baraniuk S., Simpson L.M., et al. Long-term follow-up of participants with heart failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation 2011;124:1811—1818.
  149. Pfeffer M.A., Claggett B., Assmann S.F., et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015;131:34—42.
  150. Aronow W.S. Ahn C., Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 1997;80:207—209.
  151. van Veldhuisen D.J., Cohen-Solal A., Bohm M., et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009;53:2150—2158.
  152. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777—781.
  153. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456—2467.
  154. Lee D.S., Gona P., Vasan R.S., et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 2009;119:3070—3077.
  155. Bhuiyan T., Maurer M.S. Heart failure with preserved ejection fraction: persistent diagnosis, therapeutic enigma. Curr Cardiovasc Risk Rep 2011;5:440—449.
  156. Kato S., Onishi K., Yamanaka T., et al. Exaggerated hypertensive response to exercise in patients with diastolic heart failure. Hypertens Res 2008;31:679—684.
  157. St Gyalai-Korpos I., Tomescu M., Pogorevici A. Hypertensive acute pulmonary oedema as expression of diastolic heart failure. Rom J Intern Med 2008;46:153—157.
  158. Klahr S., Levey A.S., Beck G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330:877—884.
  159. Ruggenenti P., Perna A., Loriga G., et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005;365:939—946.
  160. Wright J.T. Jr, Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421—2431.
  161. Upadhyay A., Earley A., Haynes S.M., et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011;154:541—548.
  162. Jafar T.H., Stark P.C., Schmid C.H., et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244—252.
  163. Heerspink H.J.L., Brantsma A.H., de Zeeuw D., et al. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 2008;168:897—905.
  164. Heerspink H.J.L., Gansevoort R.T., Brenner B.M., et al. Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol 2010;21:1355—1360.
  165. Contreras G., Greene T., Agodoa L.Y., et al. Blood pressure control, drug therapy, and kidney disease. Hypertension 2005;46:44—50.
  166. Esnault V.L.M., Brown E.A., Apetrei E., et al. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther 2008;30:482—498.
  167. Marin R., Ruilope L.M., Aljama P., et al. A random comparison of fosinopril and nifedipine GITS inpatients with primary renal disease. J Hypertens 2001;19:1871—1876.
  168. Giatras I., Lau J., Levey A.S. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997;127:337—345.
  169. Muntner P., Anderson A., Charleston J., et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010;55:441—451.
  170. James P.A., Oparil S., Carter B.L., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507—520.
  171. National Clinical Guideline Centre (UK). Chronic Kidney Disease (Partial Update): Early Identification and Management of Chronic Kidney Disease in Adults in Primary and Secondary Care. London, UK: National Institute for Health and Care Excellence (UK); 2014.
  172. Mancia G., Fagard R., Narkiewicz K., et al. 2013ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159—2219.
  173. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl (2011) 2012;2(5):337—414.
  174. Kanno A., Metoki H., Kikuya M., et al. Usefulness of assessing masked and white-coat hypertension by ambulatory blood pressure monitoring for determining prevalent risk of chronic kidney disease: the Ohasama study. Hypertens Res 2010;33:1192—1198.
  175. Terawaki H., Metoki H., Nakayama M., et al. Masked hypertension determined by self-measured blood pressure at home and chronic kidney disease in the Japanese general population: the Ohasama study. Hypertens Res 2008;31:2129—2135.
  176. Minutolo R., Gabbai F.B., Agarwal R., et al. Assessment of achieved clinic and ambulatory blood pressure recordings and outcomes during treatment in hypertensive patients with CKD: a multicenter prospective cohort study. Am J Kidney Dis 2014;64:744—752.
  177. Drawz P.E., Alper A.B., Anderson A.H., et al. Masked hypertension and elevated night time blood pressure in CKD: prevalence and association with target organ damage. Clin J Am Soc Nephrol 2016;11:642—652.
  178. Agarwal R., Andersen M.J. Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int 2006;69:1175—1180.
  179. Navaneethan S.D., Schold J.D., Arrigain S., et al. Cause-specific deaths in non-dialysis-dependent CKD. J Am Soc Nephrol 2015;26:2512—2520.
  180. Matsushita K., van der Velde M., Astor B.C., et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Chronic Kidney Disease Prognosis Consortium. Lancet 2010;375:2073—2081.
  181. Goff D.C.Jr, Lloyd-Jones D.M., Bennett G., et al. 2013ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(suppl 2):S49—73.
  182. Kovesdy C.P., Alrifai A., Gosmanova E.O., et al. Age and outcomes associated with BP inpatients with incident CKD. Clin J Am Soc Nephrol 2016;11:821—831.
  183. Weiss J.W., Peters D., Yang X., et al. Systolic BP and mortality in older adults with CKD. Clin J Am Soc Nephrol 2015;10:1553—1559.
  184. Williamson J.D., Supiano M.A., Applegate W.B., et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA 2016;315:2673—2682.
  185. Holtkamp F.A., de Zeeuw D., Thomas M.C., et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011;80:282—287.
  186. Hricik D.E., Browning P.J., Kopelman R., et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med 1983;308:373—376.
  187. Pfeffer M.A., McMurray J.J.V., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893—906.
  188. Cross N.B., Webster A.C., Masson P., et al. Antihypertensive treatment for kidney transplant recipients. Cochrane Database Syst Re. 2009;CD003598.
  189. Cosio F.G., Pelletier R.P., Pesavento T.E., et al. Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients. Kidney Int 2001;59:1158—1164.
  190. Peschke B., Scheuermann E.H., Geiger H., et al. Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients. Clin Nephrol 1999;51:290—295.
  191. Mange K.C., Cizman B., Joffe M., et al. Arterial hypertension and renal allograft survival. JAMA 2000;283:633—638.
  192. Mange K.C., Feldman H.I., Joffe M.M., et al. Blood pressure and the survival of renal allografts from living donors. J Am Soc Nephrol 2004;15:187—193.
  193. Taler S.J., Textor S.C., Canzanello V.J., et al. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf 1999;20:437—449.
  194. Taler S.J., Textor S.C., Canzanello V.J., et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation 1996;62:1588—1592.
  195. Woodle E.S., First M.R., Pirsch J., et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008;248:564—577.
  196. Vincenti F., Schena F.P., Paraskevas S., et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008;8:307—316.
  197. Rostaing L., Vincenti F., Grinyo J., et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 2013;13:2875—2883.
  198. Opelz G., Dohler B., Collaborative Transplant Study. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005;5:2725—2731.
  199. Hillebrand U., Suwelack B.M., Loley K., et al. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients. Transpl Int 2009;22:1073—1080.
  200. Wadei H.M., Amer H., Taler S.J., et al. Diurnal blood pressure changes one year after kidney transplantation: relationship to allograft function, histology, and resistive index. J Am Soc Nephrol 2007;18:1607—615.
  201. Ambrosi P., Kreitmann B., Habib G. Home blood pressure monitoring in heart transplant recipients: comparison with ambulatory blood pressure monitoring. Transplantation 2014;97:363—367.
  202. Haydar A.A., Covic A., Jayawardene S., et al. Insights from ambulatory blood pressure monitoring: diagnosis of hypertension and diurnal blood pressure in renal transplant recipients. Transplantation 2004;77:849—853.
  203. Benjamin E.J., Blaha M.J., Chiuve S.E., et al. Heart disease and stroke statistics--2017 update: a report from the American Heart Association. Circulation 2017;135:e146—603.
  204. Boan A.D., Lackland D.T., Ovbiagele B. Lowering of blood pressure for recurrent stroke prevention. Stroke 2014;45:2506—2513.
  205. Anderson C.S., Heeley E., Huang Y., et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013;368:2355—2365.
  206. Qureshi A.I., Palesch Y.Y., Barsan W.G., et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 2016;375:1033—1043.
  207. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581—1587.
  208. Hacke W., Kaste M., Bluhmki E., et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317—1329.
  209. Ahmed N., Wahlgren N., Brainin M., et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke 2009;40:2442—2449.
  210. Robinson T.G., Potter J.F., Ford G.A., et al. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol 2010;9:767—775.
  211. He J., Zhang Y., Xu T., et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA 2014;311:479—489.
  212. Wang H., Tang Y., Rong X., et al. Effects of early blood pressure lowering on early and long-term outcomes after acute stroke: an updated meta-analysis. PLoS ONE 2014;9:e97917.
  213. Zhao R., Liu F.-D., Wang S., et al. Blood pressure reduction in the acute phase of an ischemic stroke does not improve short- or long-term dependency or mortality: a meta-analysis of current literature. Medicine (Baltimore) 2015;94:e896.
  214. Bath P.M., Krishnan K. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev 2014;10:CD000039.
  215. Sandset E.C., Bath P.M.W., Boysen G., et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011;377:741—750.
  216. Qureshi A.I., Ezzeddine M.A., Nasar A., et al. Prevalence of elevated blood pressure in 563,704 adult patients with stroke presenting to the ED in the United States. Am J Emerg Med 2007;25:32—38.
  217. Leonardi-Bee J., Bath P.M., Phillips S.J., et al. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002;33:1315—1320.
  218. Castillo J., Leira R., Garcia M.M., et al. Blood pressure decrease during the acute phase of ischemic strokeis associated with brain injury and poor stroke outcome. Stroke 2004;35:520—526.
  219. Vemmos K.N., Tsivgoulis G., Spengos K., et al. U-shaped relationship between mortality and admission blood pressure in patients with acute stroke. J Intern Med 2004;255:257—265.
  220. Jauch E.C., Saver J.L., Adams H.P. Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870—947.
  221. Liu L., Wang Z., Gong L., et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res 2009;32:1032—1040.
  222. Lakhan S.E., Sapko M.T. Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis. Int Arch Med 2009;2:30.
  223. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033—1041.
  224. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J 1995;108:710—717.
  225. Lee M., Saver J.L., Hong K.-S., et al. Renin-angiotensin system modulators modestly reduce vascular risk in persons with prior stroke. Stroke 2012;43:113—119.
  226. Wang W.-T., You L.-K., Chiang C.-E., et al. Comparative effectiveness of blood pressure-lowering drugs in patients who have already suffered from stroke: traditional and Bayesian network meta-analysis of randomized trials. Medicine (Baltimore) 2016;95:e3302.
  227. Katsanos A.H., Filippatou A., Manios E., et al. Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials. Hypertension 2017;69:171—179.
  228. Arima H., Chalmers J., Woodward M., et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006;24:1201—1208.
  229. Dhamoon M.S., Sciacca R.R., Rundek T., et al. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology 2006;66:641—646.
  230. Hardie K., Hankey G.J., Jamrozik K., et al. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke 2004;35:731—735.
  231. Lovett J.K., Coull A.J., Rothwell P.M. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004;62:569—573.
  232. Toschke A.M., Gulliford M.C., Wolfe C.D.A., et al. Antihypertensive treatment after first stroke in primary care: results from the General Practitioner Research Database. J Hypertens 2011;29:154—160.
  233. Kernan W.N., Ovbiagele B., Black H.R., et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160—236.
  234. Buse J.B., Ginsberg H.N., Bakris G.L., et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162—172.
  235. Ostergren J., Sleight P., Dagenais G., et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17—24.
  236. Bavry A.A., Anderson R.D., Gong Y., et al. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension 2010;55:48—53.
  237. Emdin C.A., Rahimi K., Neal B., et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015;313:603—615.
  238. Arguedas J.A., Leiva V., Wright J.M. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev 2013;10:CD008277.
  239. Margolis K.L., O’Connor P.J., Morgan T.M., et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care 2014;37:1721—1728.
  240. Soliman E.Z., Byington R.P., Bigger J.T., et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial. Hypertension 2015;66:1123—1129.
  241. Bress A.P., King J.B., Kreider K.E., et al. Effect of intensive versus standard blood pressure treatment according to baseline prediabetes status: a post hoc analysis of a randomized trial. Diabetes Care 2017;40:1401—1408.
  242. Whelton P.K., Barzilay J., Cushman W.C., et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:1401—1409.
  243. Palmer S.C., Mavridis D., Navarese E., et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 2015;385:2047—2056.
  244. Schmieder R.E., Hilgers K.F., Schlaich M.P., et al. Renin-angiotensin system and cardiovascular risk. Lancet 2007;369:1208—1219.
  245. Kannel W.B., Wilson P.W., Zhang T.J. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 1991;121:1268—1273.
  246. Tarnow L., Rossing P., Gall M.A., et al. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994;17:1247—1251.
  247. Adler A.I., Stratton I.M., Neil H.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412—419.
  248. Stamler J., Vaccaro O., Neaton J.D., et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434—444.
  249. Do D.V., Wang X., Vedula SS, et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev 2015;1:CD006127.
  250. Estacio R.O., Jeffers B.W., Gifford N., et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(suppl 2):B54—64.
  251. Estacio R.O., Jeffers B.W., Hiatt W.R., et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645—652.
  252. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703—713.
  253. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755—1762.